iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical…
Browsing: NSCLC
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
… At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical…
March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved…
On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name…
In a recent discussion, Ticiana Leal, MD, sheds light on TD Fields treatment for non-small cell lung cancer. This innovative…
Jack West, MD is an associate professor in medical oncology specializing in thoracic oncology at the City of Hope Comprehensive…
In the pivotal phase 3 LUNAR study, Ticiana Leal, MD, and her colleagues made a groundbreaking discovery that could revolutionize…
In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital Sunvozertinib established itself as the leading targeted therapy for NSCLC…
Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, has conducted a randomized, phase 3 study called LUNAR,…
Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD…
iFrame is not supported! Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC…
Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD…
iFrame is not supported! Biomarkers RNA: [2022] What Is ASPYRE Technology? How Can This Help Patients With Non-small Cell…
Biomarkers RNA: [2022] What Is ASPYRE Technology? How Can This Help Patients With Non-small Cell Lung Cancer (NSCLC)? I…
iFrame is not supported! Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body…
Lung SBRT Dose Optimization [2022]: Overcoming Size & SUV? When Was Lung SBRT (stereotactic body radiation therapy) Treatment Developed?…
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary…
Despite the advances in precision medicine for non-small cell lung cancer (NSCLC), a significant proportion of patients, particularly African American…
Audio: Thank you, thanks for the question so this study titled IMP is an early phase dose-escalation study first in…
INT230-6 is an early phase dose-escalation study first in hand study evaluating effectiveness of a new compound called PORT-2 now…
 Article: Transcript: Question – Please Tell Us About the INVINCIBLE Trial.  Thank you, thanks for the question so…
Audio: Hi there my name is Jia Luo I’m a thoracic medical oncologist at Dana-Farber it’s very nice to speak…
Transcript: Hi there my name is Jia Luo I’m a thoracic medical oncologist at Dana-Farber it’s very nice to speak…
Plinabulin Improved OS and lower Toxicity in NSCLC EGFR Wild Type The DUBLIN-3 was a randomized phase III trial from…
Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 5 Key Conclusions:…
Co-hosts Charu Aggarwal and Jack West are joined by guest expert Sanjay Popat to discuss how practice should change and…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Terri Conneran, a lung cancer survivor and patient advocate.…